1. Pink Sheet
  2. >>Market Access
  4. >>Medicare

How The IRA Factored Into Akebia’s Price For Vafseo

 
• By Alaric DeArment

Akebia says its price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.

• Source: Shutterstock

A lot went into Akebia Therapeutics’s decision to price its chronic kidney disease (CKD) drug, Vafseo (vadadustat), at $1,278 per month, but the Inflation Reduction Act (IRA) and its impact on drug pricing were certainly part of it.

The Cambridge, MA-based company said on 11 July that it had given Vafseo a wholesale acquisition cost (WAC) of about $15,500 per patient per year based on the starting dose of the oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which cleared the US Food and Drug Administration on 27 March for anemia due to CKD

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.